Pyxis Oncology (NASDAQ:PYXS) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report report published on Monday. The brokerage issued a buy rating and a $9.00 price objective on the stock.

PYXS has been the subject of several other reports. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Zacks Research raised Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. Guggenheim started coverage on Pyxis Oncology in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $5.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pyxis Oncology presently has an average rating of “Moderate Buy” and an average price target of $8.40.

Pyxis Oncology Stock Up 0.3%

Shares of NASDAQ:PYXS opened at $3.91 on Monday. The firm has a market cap of $243.44 million, a P/E ratio of -2.44 and a beta of 1.41. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.39. The business has a fifty day simple moving average of $2.62 and a 200 day simple moving average of $1.68.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.01. As a group, equities research analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Pier 88 Investment Partners LLC increased its position in Pyxis Oncology by 296.6% in the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after buying an additional 292,370 shares in the last quarter. Schulhoff & Co. Inc. increased its position in Pyxis Oncology by 125.4% in the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares in the last quarter. 683 Capital Management LLC increased its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after buying an additional 135,000 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new stake in Pyxis Oncology in the 2nd quarter valued at about $37,000. Finally, Nuveen LLC bought a new stake in Pyxis Oncology in the 1st quarter valued at about $125,000. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.